MAM
Mia by Tanishq launches new digital film for ‘Facets Collection’
MUMBAI: Mia by Tanishq, has announced the launch of another incredible range, the Facets collection. It is a contemporary collection designed for every woman who has a unique blend of moods which makes her special and exceptional in her everyday life. This set of jewellery brings together designs, colours, and stones for every mood of a woman.
Conceptualised by Fryed Advertising, the TVC captures every emotion of a woman right from being happy to goofy and from bored to flirty.
The customisation aspect highlights on how Mia celebrates the special multi – mood characteristics of every woman. This modern range of jewellery comes up with unique designs which include angles, cubes, and varied coloured stones that in turn reflect every spirit of a woman.
Speaking about the latest collection, Mia by Tanishq brand head Bhavishya Kelappan said, “With the launch of our latest Facets Collection, Mia has redefined the contemporary jewellery category as we understand that Jewellery is an element of self-expression. We believe that a woman expresses her mood not only through her attire, but also through the jewellery she chooses for the day. Our latest Facets collection includes designs that reflect every mood of a woman. The TVC clearly highlights our key proposition of the unique collection available that perfectly complements the various moods of the women of today.”
Fryed Advertising partner Prahlad Nanjappa said, “The Facets Collection led us to visually echo the many sides of a woman. Our commercial showcases many girls – until you realize that they’re all the same person, and her many moods interacting with each other. Catch this interesting campaign, and shop for Mia By Tanishq’s brand-new Facets collection – when you’re in a #TreatYourself mood!”
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
